Typed or printed name

Maribel Mendez

P. 1

RECEIVED CENTRAL FAX CENTER

AUG 2 3 2005

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number

10/24 055 TRANSMITTAL Filing Date September 22, 2003 First Named Inventor **FORM** Gerhard JAEHNE et al. Art Unit 1821 Examiner Name NWAONICHA, Chukwuma O. (to be used for all correspondence after initial filing) Attorney Docket Number 13 pgs. DEAV2001/0045 US NP 2 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) 6 Petition Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) 1. Supplemental Amendment and Reply - 12 pgs. Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1,53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC. Signature Printed name Balaram Guota Date Reg. No. August 23, 2005 40.009 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: [USPTO FAX NO. 571-273-8300 Total No, of Pages Transmitted: Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

August 23, 2005

AUG 2 3 2005

PATENT

Docket No.: DEAV2001/0045-US-NP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Gerhard Jaehne, et al.

Examiner:

Nwaonicha, Chukwuma O.

Art Unit:

1621

Serial No.: 10/664,855

Filed:

September 22, 2003

TELEFAX CERTIFICATE

Title:

C2-Substituted Indan-1-ols and Their

Derivatives, Processes for Their Preparation and Their Use as

Pharmaceuticals

I hereby certify that this correspondence is being transmitted via facrimile to the Commissioner for Patents, Alexandria, VA 22313, at (571) 273-8300 on

Signature Menos

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Arlington, VA 22313-1450

SUPPLEMENTAL AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 AND REPLY PURSUANT TO 37 C.F.R. § 1.111

Sir:

This is a supplemental response and Rule 111 Amendment in the above-identified patent application in response to telephone call initiated by the Examiner on August 22, 2005. It is respectfully requested that the following remarks be entered in this case.

Amendments to claims start on page 2.

Remarks to amendments and the outstanding office action begin on page 11.

DEAV2001/0045-US-NP2

-1 of 12-